Transcranial Pulse Stimulation for Depression

Status Recruiting

Clinical Trial Summary

Transcranial pulse stimulation (TPS) is a newly developed brain stimulation therapy from Austria & Germany with highly promising applicability in neuropsychiatric disorders. Major depressive disorder (MDD) is the world's leading cause of disability. Novel treatment approaches are urgently needed given that a significant fraction of patients does not sufficiently respond to standard antidepressant treatments. Our open-label pilot study using TPS in MDD indicates preliminary efficacy. However, experimental control is necessary to infer reliable scientific evidence for the efficacy of TPS. Here, we propose a randomized, double-blind, sham-controlled clinical trial to probe the utility of TPS as a modern antidepressant treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05551585
Study type	Interventional
Source	The Hong Kong Polytechnic University
Contact	Georg Kranz, PhD
Phone	27664838
Email	georg.kranz@polyu.edu.hk
Status	Recruiting
Phase	N/A
Start date	June 1, 2023
Completion date	January 2025

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03062150` - Mineralocorticoid Receptor, NMDA Receptor and Cognitive Function in Depression	N/A
Completed	`NCT04352101` - Bupropion Versus Escitalopram on Reward Circuitry and Motivational Deficits	Phase 4
Completed	`NCT02855918` - Blood Biomarkers in Suicidal Behaviour	N/A
Recruiting	`NCT03039387` - Effects of tDCS on Cognitive Control and Emotion Regulation in Depressed Patients	N/A
Recruiting	`NCT02213016` - Effectiveness of Repetitive Transcranial Magnetic Stimulation in Depressed Patients	Phase 4
Completed	`NCT01636791` - CBT Versus a Return to Work Intervention for Patients With Common Mental Illness in Primary Care	Phase 3
Completed	`NCT01683539` - Understanding How Cognitive Remediation Works	N/A
Recruiting	`NCT02237937` - Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene	Phase 4
Completed	`NCT01201148` - Open Pilot Trial of TES for Depression	Phase 2
Completed	`NCT00953108` - Quetiapine Prolong, Escitalopram and Hypothalamic-pituitary-adrenocortical (HPA) Axis Activity in Depressed Patients	Phase 3
Terminated	`NCT01244711` - Open-Label Pilot Study to Examine the Value of Substituting Quetiapine for Benzodiazepines	Phase 4
Terminated	`NCT00695552` - The Effect of Exercise on Depressive Symptoms in Unmedicated Patients	N/A
Completed	`NCT00806143` - Bilateral Versus Monolateral Repetitive Transcranial Stimulation in Depression	Phase 4
Completed	`NCT00711737` - Study of the Changes in Metabolic Parameters in Patients Treated With Escitalopram for Six Months	N/A
Completed	`NCT00532480` - Study of Brain Response to Emotional Pictures Using a fMRI While on Duloxetine	Phase 4
Completed	`NCT00482482` - Yoga in Unipolar and Bipolar Disorders	N/A
Completed	`NCT00466323` - The Effectiveness of FMPO in Improving the Quality of Care for Persons With Severe Mental Illness.	N/A
Completed	`NCT00616759` - The Effect on Cognition of Terminating ECT Induced Seizures With Propofol	N/A
Recruiting	`NCT00209807` - Effect of Escitalopram vs. Reboxetine on Gastro-intestinal Sensitivity of Patients With Major Depressive Disorder	Phase 4
Completed	`NCT00167310` - Decreasing Risk of Coronary Artery Disease in Schizophrenia by Omega-3 Fatty Acid Supplementation	Phase 2